PMID- 33830442 OWN - NLM STAT- MEDLINE DCOM- 20211210 LR - 20220218 IS - 1699-3055 (Electronic) IS - 1699-048X (Print) IS - 1699-048X (Linking) VI - 23 IP - 9 DP - 2021 Sep TI - Synchronous bilateral breast cancer treated with a 3-week hypofractionated radiotherapy schedule: clinical and dosimetric outcomes. PG - 1915-1922 LID - 10.1007/s12094-021-02600-1 [doi] AB - BACKGROUND AND PURPOSE: Synchronous bilateral breast cancer (SBBC) accounts for 1-3.5% of breast cancer patients. The aim of this study was to evaluate dosimetric issues, clinical outcomes, and acute toxicities for SBBC patients receiving synchronous bilateral hypofractionated radiotherapy (SBHRT) and to compare them with patients treated with synchronous bilateral normofractionated RT schedule (SBNRT). MATERIALS AND METHODS: From April 2016 to March 2020, 39 SBBC patients were referred to our institution. Patients were divided according to their prescription dose: Group A: 50 Gy/25fx (fractions), B: 60-64 Gy/25fx, C: 40.05 Gy/15fx; D: 48 Gy/15fx. Toxicity was evaluated using Common Terminology Criteria for Adverse Events (CTCAE)v.5.0. RESULTS: 34 patients were finally evaluated. Median follow-up was 24 months for NF schedule and 9 months for HF schedule. In the HF schedule, no acute side-effects > G2 were observed and no dermatitis was reported in 6(th) month s assessments. 95% of patients have no evidence of disease and only 1 patient presented local relapse in the first mammography after RT. No distant failures or deaths were observed. Regarding dosimetric issues, the inter-patient average D(mean) for the heart was: Group A: 5.0 Gy (4.6-5.5), Group B: 4.4 Gy (4.1-5.4), Group C: 4.8 Gy (4.5-5.1) and Group D: 5.3 Gy (4.4-5.6). For the lungs, the inter-patient average D(mean) was: Group A: 10.8 Gy (9.8-12.2), Group B: 11.5 Gy (11.3-12), Group C: 9.8 Gy (9.3-10.5) and Group D: 10.5 Gy (10-11.3). CONCLUSIONS: This is the first study reporting the safety, feasibility, and tolerability of 40.05 Gy/15fx over 3 weeks for the treatment of SBBC patients. Further study with larger accrual is mandatory. CI - (c) 2021. Federacion de Sociedades Espanolas de Oncologia (FESEO). FAU - Gadea, J AU - Gadea J AUID- ORCID: 0000-0002-6210-8469 AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. jongadea@gmail.com. FAU - Ortiz, I AU - Ortiz I AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. AD - Institut d Investigacio Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain. FAU - Roncero, R AU - Roncero R AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. FAU - Alastuey, I AU - Alastuey I AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. AD - Institut d Investigacio Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain. FAU - Mestre, F AU - Mestre F AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. AD - Institut d Investigacio Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain. FAU - Aymar, N AU - Aymar N AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. AD - Institut d Investigacio Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain. FAU - Maturana, J E AU - Maturana JE AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. FAU - Garcia, C AU - Garcia C AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. FAU - Mateu, L AU - Mateu L AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. FAU - Pardo, J AU - Pardo J AD - Hospital Universitari Son Espases, Radiation Oncology Department, Carretera de Valldemossa, 79, 07020, Palma de Mallorca (Islas Baleares), Spain. AD - Institut d Investigacio Sanitaria Illes Balears, IdISBA, Palma de Mallorca, Spain. AD - Hospital Universitari General de Catalunya, Sant Cugat del Valles, Spain. LA - eng PT - Journal Article PT - Observational Study DEP - 20210408 PL - Italy TA - Clin Transl Oncol JT - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico JID - 101247119 SB - IM MH - Breast Neoplasms/diagnostic imaging/*radiotherapy/surgery MH - Feasibility Studies MH - Female MH - Follow-Up Studies MH - Heart/radiation effects MH - Humans MH - Lung/radiation effects MH - Neoplasms, Multiple Primary/diagnostic imaging/*radiotherapy/surgery MH - Organs at Risk/radiation effects MH - Prospective Studies MH - *Radiation Dose Hypofractionation MH - Radiotherapy, Intensity-Modulated/adverse effects MH - Time Factors PMC - PMC8026808 OTO - NOTNLM OT - Acute toxicity OT - Breast cancer OT - Hypofractionated radiotherapy OT - Radiation therapy OT - Synchronous bilateral breast cancer OT - Volumetric modulated arc radiotherapy COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2021/04/09 06:00 MHDA- 2021/12/15 06:00 PMCR- 2021/04/08 CRDT- 2021/04/08 12:47 PHST- 2021/02/09 00:00 [received] PHST- 2021/03/15 00:00 [accepted] PHST- 2021/04/09 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/04/08 12:47 [entrez] PHST- 2021/04/08 00:00 [pmc-release] AID - 10.1007/s12094-021-02600-1 [pii] AID - 2600 [pii] AID - 10.1007/s12094-021-02600-1 [doi] PST - ppublish SO - Clin Transl Oncol. 2021 Sep;23(9):1915-1922. doi: 10.1007/s12094-021-02600-1. Epub 2021 Apr 8.